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1. Introduction
Most of the currently known infections represent a persistent and stepwise development
of the canonical chronic diseases of infectious origin (CDIO) associated with conditionally
pathogenic microorganisms,  i.e.,  viruses,  intracellular parasites and other representatives
of  the  endogenous  microbiome,  particularly,  those  manifesting  with  atypical  properties.
Pathogens are able to interact between themselves and to cause a disease, and the patho‐
gens’ genomes break the subtle regulation of microbial ecosystems (microbiomes) (Suchkov
et al., 2007).
The aforementioned studies have led to a reappraisal of Koch’s postulates to announce that
he had shown theoretically more then a hundred years before: one microbe causes one dis‐
ease. Interactions of microbial pathogens with specific tools of the patient’s immune machi‐
nery in due the course of the infectious process give rise to different types of micro-biocenosis
to manifest a broad range of activities of the microbiome-related pathogens including their
ability to suppress the immune response.
The key role of immune-related and microbial factor in CDIO pathogenesis is evidently
proved today. However, a comparison of types of the patient’s individual immune respons‐
es and the features of microbial landscapes with the clinical manifestations of the disease (clini‐
cal pattern) by singling out postinfectious clinical-and-immunological syndrome (PICIS) as a
pathogenically oriented category and a fundamental term is appearing to be a more compli‐
cated objective to be cleared.
© 2013 Cherepahina et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
As many authors established, for CDIО-related specific form of PICIS has clinical and prog‐
nostic significance and informative and thus predictive value, because, for sure, PICIS deter‐
mines to a considerable degree the extant of progressing and chronization of the underlying
disease whilst determining risks of complications.
Postinfectious secondary immunodeficiency syndrome (PIFSI) is a monosyndromal and pre‐
dominant form of PICIS in patients with CDIO.
More than in a third of cases another form of PICIS could be formed and thus observed, ac‐
companying by postinfectious autoimmune syndrome (PIFA) reflecting the involvement of
immune-mediated autoaggression, or PIFASID as an associated form of immune imbalance.
The susceptibility to one or another form of CDIO-associated PICIS depends on a number of
genetically determined factors, which play a crucial role in formation of the patient’s immune
resources via cooperation between mechanisms of innate and adaptive immunity (Fig. 1).
Note: NK, natural killer
Figure 1. Main features of innate and adaptive immunity
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Unfortunately, the role of these mechanisms in the development and chronization of infec‐
tious diseases is still obscure, which deprives a doctor of the possibility to improve the cur‐
rently available models of CDIO chronization with the ultimate goal to develop the most
advanced treatment-and-rehabilitation in a package of the preventive treatment protocols,
and their implementation into routine and daily clinical practice (Paltsev et al., 2009a).
The key role in the chronization and thus complications of such diseases, and thus the de‐
velopment of the associated immune disorders is played by:
i. properties of the infectious agent;
ii. type of a patient’s immune response.
The microbial factor may promote development of a vast array of the associated immune
disorders and thus forms of immune-mediated pathologies (PICIS), particularly, owing the
microorganisms to gain, in the running course of the disease evolution, a large arsenal of in‐
trinsic tools enabling microbes to escape from attacks of immune-mediated weapon, to at‐
tenuate and the latter whilst getting them weakened or to influence the dynamics of the
clinical manifestations of PICIS itself. Actually, the severity and duration of CDIO depends
on the interaction between the microbiome and the antimicrobial immunity machinery (Palt‐
sev et al., 2009b).
2. PICIS and its role in the state-of-the-art model of immunopathogenesis
of chronic infectious diseases
The PICIS variants include:
1. postinfectious secondary immunodeficiency syndrome (PIFSIS);
2. postinfectious autoimmune syndrome (PIFAS);
3. PIFAS coupled with PIFSIS (PIFASID) (Suchkov et al., 2004).
The occurrence and thus incidence of these syndromes in CDIO patients differs statistically
depending on the form of a type of the primary infection and the stage of the destructive
inflammatory process in the targeted organs or tissues. For example, the initial (including
subclinical) stages of any clinical courses of CDIO are usually concomitant with a predomi‐
nant (>50%) formation of PIFSIS, while the quotes of PIFAS and PIFASID do not exceed
20%.
This situation changes with further development and chronization of the infectious process
and its transformation from a subclinical into the clinical stage, viz., the incidence of autoim‐
mune syndromes increases substantially. In intermediate stages of chronization, the quotes
of PIFAS reach 50%, whilst in the final stages of chronization similar indices of PIFASID
reach 60%.
It may thus be concluded that PIFSIS is not only the outcome of the infectious process, but,
rather, the major factor responsible for provoking complications and raising thus a chronic
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relapsing course. The role of progression and chronization of the disease is determined, in a
large measure, by the form of PICIS or, rather, of PIFAS and PIFASID, which reflect the
manifestations and thus a pattern of postinfectious autoaggression (Suchkov et al., 2004).
3. Microbiome and its role in the state-of-the-art model of CDIO
pathogenesis
A crucial role in CDIO pathogenesis is played by primary and superinfectious factors en‐
dowed with the ability to generate large microbial associates. Therefore, the features of the
patient’s microbiome are key etiopathogenic links for realization of the infection-associated
chronization phenomenon.
Notes: Ag, antigen
Figure 2. Scenarios of interactions between a microbial pathogen and the patient’s antimicrobial immune response
illustrating an escape from the immune supervision to survive
Moreover, in a course of their evolution microorganisms acquire a vast array of molecular
and cellular tools enabling them to escape from the intrinsic control of the immune system
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over the microbiome itself, to switch off mechanisms of the control over the microbiome, or
to initiate changes underlying the resistance phenomenon (Fig. 2). As a result of the antago‐
nistic interactions between a microbe and the antimicrobial immunity machinery, the im‐
mune response is either not elicited at all or is only partly activated giving rise to
manifestations of PIFSIS, or progressing in a form provoking either PIFAS or PIFASID. This
is concomitant with the formation of membrane films by clinical isolates of pathogenic mi‐
croorganisms escaping from the control of antimicrobial agents.
In 30% of cases, the causative agent is not cultivated, but, rather, is converted into the L-
form, which does not exclude the presence of an “invisible” pathogen in the course of the
instrumental and laboratory diagnostics procedures, and implies the latent progress of the
infectious process. The latter presents particular interest because the conversion of some mi‐
croorganisms into the latent (cryptic or sleeping) form is one of the ways to chronization by
escaping from the proper immune response.
4. Features of microbial spectra in CDIO patients
Conventional (predominantly, gram-negative) bacterial flora is detected in the majority of
CDIO patients, though the results of the recent studies testify not only to the growth of
gram-negative microorganisms, but also to a dramatic increase in the number of superinfec‐
tious pathogens of viral and parasitic origin.
The results of our recent studies suggest that the most frequently occurring human infec‐
tions may conventionally be divided into two main categories:
1. susceptibility to relapsing infections provoked by pyogenic bacteria (S. pneumoniae, S.
aureus, etc.) with a minimum mimicking resource increases dramatically in patients
whose disorders are linked with antibody (Ab), complement and phagocytosis deficien‐
cy, PIFSI being the predominant form of PICIS;
2. a particular susceptibility to viral and intracellular pathogens endowing with a high
mimicking potential increases in patients with disturbances in primary cell-mediated im‐
munity (Fig. 3)
Fluorescence has been used to show that the process of intraintestinal hatching of Trichuris
muris is critically dependent on the attachment of an enterobacterium to the polar opercu‐
lum of the egg (Panel A). Hatched worms attach to the bowel wall and induce activation of
type 2 helper T (Th2) cells, which in turn inhibit the proliferation and differentiation of type
17 helper T (Th17) and regulatory T (Treg) cells. In contrast, worm development was halted
and specific immune responses were altered in mice that were depleted of gram-negative
enterobacteria by antibiotics (Panel B), underscoring the influence of the intraintestinal envi‐
ronment on intestinal immune responses.
At the same time intracellular pathogens interfere in cell nucleus during DNA transcrip‐
tion. One of the key mechanisms by which microbes achieve the immunosuppressive ef‐
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fects  is  by  subverting  one  of  the  body’s  most  prolific  nuclear  receptors,  the  vitamin  D
receptor  (VDR).  Defects  in  VDR  signaling  transduction  have  previously  been  linked  to
bacterial  infection and chronic inflammation. Each pathogen that decreases VDR expres‐
sion makes  it  easier  for  other  pathogens  themselves  to  slow immune activity  even fur‐
ther, creating a snowball effect.
Figure 3. Hatching Parasites
However, a complete set of mechanisms by which persistent intracellular microbes slow in‐
nate immune activity has yet to be definitively determined (Proal A. D. et al. 2011). In such
patients, these microorganisms provoke fast progressing infections associated with PIFA or
moderate PIFSI with an impending transformation of PIFSI into PIFASID.
Microbiomes detected and properly assessed in the course of chronization and progression
of CDIO are characterized by a high degree of multiplicity and variability, which have every
right to be regarded as clinically important chronization criteria regardless of the nosologi‐
cal form of the disease. At the same time, the intrinsic architectonics of microbiomes varies
widely depending on the microbial category:
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1. in some cases (ICIIP and COPD/CP), the dominant is common to all microbial catego‐
ries (including the total virulent resource/TVR);
2. for other categories (e.g., CPN), the bacterial dominant (which is TVR-limited) displays,
contrary to ICIIP and COPD/CP, a “gap” in both specific ratio and virus variety;
3. in certain disorders (e.g., chronic myocarditis/CM), the specific ratio of bacteria and
their TVR tend to minimum against the background of an absolute viral dominant.
5. Features of interactions between patient’s antimicrobial immunity and
etiopathogens during PICIS formation in the course of disease
progression
The main feature of the defense immune response to the infective pathogen is formation of
two subpopulations of regulatory T helper cells (Th cells). Effector CD4+ Th cells divide into
Th-1, Th-2, Th-3 and Th-17 subpopulations depending on cytokines secreted, transcription
factors and signal pathways. Th1 cells trigger effector mechanisms of cell-mediated immuni‐
ty, and Th2 cells are responsible for antibody (Ab) formation (Mc Guirk et al., 2002) (Fig. 4).
Th3 cells (or regulatory Treg-cells) are the other clone of cells expressing CD4+ and CD25+.
They are able to regulate functions of Th1/Th2 subpopulations and to maintain immune ho‐
meostasis (Sakaguchi, 2004; Shevach, 2002).
Th3 cells come from thymic CD4+ progenitor cells in the presence of IL-2 and TNF-β. Naive
At the periphery CD4+ T cells can be converted by the signals transmitted through STATS in
the presence of TNF-β into inducible Treg expressing transcription factor FoxP3 (Koenen,
2008). These cells are characterized also by low level of IL-2 and IFN-γ production and high
level of IL-10, IL-35, TGF- β production. Two regulatory or proinflammatory cytokines,
IL-10 and TNF-β, mediate suppression of the immune responses against autoAgs and thus
prevention of autoimmune diseases.
Note: Ag, Lc, IL, NK, GM-CSF, TNF, IFN, LT, MP, antigen, leukocyte, interleukin, natural
killer cell, granulocyte-monocyte colony-stimulating factor, tumor necrosis factor, interfer‐
on, leukotriene, macrophage, respectively; Th, T helper cell.
The development of autoimmune diseases was previously associated only with Th1 cells,
but absence of IFN-γ not only prevents development of autoimmunity in mice, but acceler‐
ates process. This fact has lead to discovery of a separate subclone of T cells, differing from
Th1 cells and capable of inducing local inflammation and autoimmunity.
This clone (Th17) is derived from naive CD4+ T cells in response to stimulation with IL-6,
IL-23, IL-1β, TGF-β (Stochinger et al., 2007). IL-6 and IL-23 activate STAT3, which enhances
the expression of transcription factors RORyt RORy, which in turn increase the expression
of major cytokines of the clones - IL17A; IL17F; IL21; IL22 (Dyachenko & Dyachenko, 2010).
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Figure 4. Ag-specific differentiation of T cells in two main-line directions and formation of regulatory Th1, Th2 cells
Thus, the differentiation of T cells is a result of the coordinated activity of cytokines and
transcription factors. At the same time TGF-β produced by dendritic cells and macrophages
may send differentiation of naive T cells both in the direction of Treg cells (CD4 + CD25 +
FoxP3+), and in the direction of Th17 cells producing IL-17 (Aarvak, 2009; Chabaud et al..
2001).. It occurs as a result of the expression of transcription factor FoxP3 and RORyt, which
are important for the differentiation of Treg or Th17cells, respectively.
High concentrations of TGF-β stimulate production of FoxP3, which block the expression of
genes associated with RORyt, resulting in the differentiation of naive CD4 + T-cells in ROR‐
yt, and it leads to the differentiation of Th17 cells and expression of IL-17 (Volpe et al., 2008;
Zhou et al., 2008).. It is believed that FoxP3 rivals with RORyt through physical interaction,
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while the inflammatory mediators IL-6 and IL-21 implement their inhibitory effect on post-
translational level (Zhou et al., 2008).
Th17 cell line plays an important role in protection against a variety of microorganisms,
have a strong proinflammatory effect by expressing IL-17. IL-17 promotes an expansion and
recruitment of innate-related immune cells such as neutrophils enhances the inflammatory
nuclear reactions together with TLR-ligands, IL-1β, TNF-α and stimulates the production of
beta defensives and other antimicrobial peptides (Vojdani et al., 2006a, Vojdani et al., 2006b,
Vojdani et al., 2006c, Chung et al., 2009; McGeachy et al., 2009). IL-17RA (its receptor) has
common characteristics with classical receptors of innate immunity, and its intracellular tail
domain transmits a signal over a general inflammatory transduction pathway, thus linking
the innate and adaptive immunity.
The role of Th17 is not clear in case of viral and parasitic infections. Thus, for instance, Th17-
induced response inhibits apoptosis of virus-infected cells and contributes to the persistence
of the virus. Tissue infiltrated with activated Th17 lymphocytes producing significant
amounts IL-17, IL-26, IL-21, IL-22, TNF-α and lymphotoxin-B in chronic inflammation (Yu et
al;., 2009; Cho et al., 2004). Production of these cytokines is inversely related with the pro‐
duction of Th-1 and Th-2 cytokines.
Localization of etiopathogen, i.e., out-or intracellular, is a factor determining the develop‐
ment of a particular immune response and, therefore, one or other form of PICIS as a result
of specific immune response (Mazo et al., 2007; Litvinov et al., 2008; Zhmurov et al., 2000;
Rumyantsev & Goncharova, 2000).
The latter circumstance is important not only to the pathogenesis, but also from a clinical
point of view, since much of the pathogens that have the ability to escape from immune re‐
sponse, also create unpredictable risks of complications and difficulties with the choice of
treatment scheme. Herewith therapy should be personalized, taking into account the spectra
of producing cytokines: IFN-y (Th1); IL-4, IL-5, IL-13 (Th2); IL-17 (Th17). The aim of such
therapy may be the modulation effects caused in separate factors, cytokines, and transcrip‐
tion factors.
In so doing, the crucial factor responsible for the development of one or another type of the
immune response and, accordingly, one or another form of PICIS is extra- and intracellular
localization of the etiopathogen. The latter is important not only from the pathogenic, but
also from the clinical point of view, because a considerable amount of pathogens escaping
from the immune response involve unpredictable complications and difficulty in the choice
of treatment strategies (Antonov & Tsinzerling, 2001; Borisov, 2000; Kukhtevich et al., 1997;
Morozov, 2001 Paukov, 1996).
According to our original data, at least three forms of PICIS, viz., PIFSI, PIFA and PIFA‐
SID, are identified in the paradigm of immune pathologies associated with the underly‐
ing disease.
PIFSIS is a dominant monosyndromal form of associated immune pathologies. In other cas‐
es, we deal with the formation of a different clinical immunologic syndrome reflecting auto‐
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immune PIFA aggression. In some patients, a combination of PIFSIS and PIFAS gives rise to
the appearance of the bisyndromal form of immunopathology (PIFASID).
6. Forms of PICIS
6.1. PIFSI
Abatement of antimicrobial protective mechanisms due to deficiency of innate immunity
concomitant with imbalances in the adaptive branch is a crucial feature of PIFSIS, which
manifests itself as a chronic disease (presumably, of bacterial and mixed origin). Suppres‐
sion of the activity of its effector links markedly weakens the patient’s response to the infect‐
ing pathogen resulting in the persistence of the pathogenic microorganism, or
superinfection with conditionally pathogenic microorganisms maintaining low-intensity
processes.
6.2. PIFAS
Many proteins from pathogens share structural similarities with human proteins, and those
can also contribute to autoantibody (autoAb) production (Fig. 5). Lekakh et al. found that
polyspesific autoAbs harvested from sera of healthy donors were able to cross-react with
DNA and lipopolysaccharides of bacterial strains including Escherichia coli, Pseudomonas aer‐
uginosa, Shigella boydii, and Salmonella. Furthermore, since human Abs are polyspecific, it is
likely that some of them produced to target pathogens may mistakenly target human pro‐
teins, causing ‘collateral damage’ (Khitrov et al., 2007).
In  the  course  of  CDIO  progression,  a  portion  of  autoreactive  cytotoxic  T  lymphocytes
(CTL) able to interact with cross-reacting microbial Ags associated with pathogen-condi‐
tioned infection undergo activation under the influence of various factors including mo‐
lecular mimicry (Khitrov et al., 2007a; Fujinami et al., 2006; Rose & Mackay, 2000; Benoist
& Mathis, 2001).
The consequences of this phenomenon manifest themselves during recognition of autoepi‐
topes by autoreactive CTL as a result of which PIFAS acquires an ability to attack any organ
or tissue in the infected host. The risk of development of this syndrome increases dramati‐
cally with increasing morbidity from infectious diseases and at high rates of pathogen flows,
as, e.g. in mixed infections (Sanaev et al., 2007; Cherepakhina et al., 2010a).
At present, there exist three explanations for the associative interplay between the infection
and the risks of PIFAS occurrence based on activation of autoreactive clones of T and B cells:
a. activation of microbial superAgs;
b. leakage of cryptic (intramolecular) autoepitopes;
c. molecular mimicry (Bauer et al., 2001; Bingen-Bidois et al., 2002; Blackwell et al., 1987;
Carballido et al., 2003; Dantzer & Wollman, 2003).
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Note: The presence, in microbial pathogens, of Ags cross-reacting with or mimicking patient’s Ags attenuates the pa‐
tient’s protective response by changing the direction of the infectious process. Activation of self-reactive CTL and pro‐
duction of Abs able to cross-react with both microbial epitopes and epitopes of the infected patient Abs in the
paradigm of molecular/Ag mimicry underlies PIFA. Ag, antigen; Ab, antibody; APC, antigen-presenting cell; T, T lym‐
phocyte; CTL, cytotoxic T lymphocyte; PIFAS, postinfectious autoimmunity syndrome
Figure 5. Molecular (Ag) mimicry and its role in PIFA induction
The aforementioned pathogenic mechanisms are not mutually exclusive and play an essen‐
tial role in certain (early, as a rule) stages of the CDIO development as well as in PIFAS asso‐
ciated with the underlying disease. In other words, the induction stimuli for PIFA at the
initiation point are as follows:
a. Ag features of the microbial pathogen;
b. tropism of the infectious pathogen to cells, organs and tissues against which the cyto‐
pathic effect is specifically directed (Sanaev et al., 2008; Cherepakhina et al., 2009).
Contrary to PIFSIS, in patients with PIFAS all the three categories of antimicrobial Abs (anti‐
bacterial, antiviral, antiparasitic) have high incidence. If the incidence and high titers of anti‐
bacterial and antiviral Abs are approximately equal in the majority of patients, antiparasitic
Abs are present in maximum titers in some forms of the disease (e.g. CPN and CM), but are
absent in others (ICIIP), most probably due to specific peculiarities of the underlying disease
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rather than mechanisms of PIFA formation (Vinnitskij, 2002; Kolesnikov et al., 2001; Chere‐
pakhina et al., 2010b).
Autoaggression provoked by an improper cooperation between both branches of immunity
as a result of adaptive branch hyperfunction is a dominant feature of PIFAS (Shogenov et
al.,2006).
Its key factors include a wide variety of anti-organ and anti-tissue auto-Abs able to promote
multiple seropositivity and appearance of autoimmune inflammation markers (e.g., anti-B7-
HI-auto-Ab). By illustration, the presence of antimyelin and antineuronal auto-Abs is typi‐
cally specific for patients with ICIIP; anti-THG auto-Abs are specific markers of
autoimmune inflammations in renal tissue of patients with CPN, while anti-CMC auto-Abs
are typical of patients with CM (Shogenov et al., 2010).
The most informative PIFAS models include autoimmune myocarditis (AIM), autoimmune
encephalomyelitis (AEM) and ICIIP, autoimmune hepatitis (AIH), autoimmune colienteritis
(ACE), autoimmune pancreatitis (AIP), autoimmune gastritis (AIG), autoimmune (strepto‐
coccal) glomerulonephritis (AGN), etc.
6.3. PIFASID
This syndrome combines the abnormalities of the both branches of immunity and is clini‐
cally characterized by the presence of mixed immunopathology (PIFAS+PIFSIS). The asso‐
ciated  disorders  in  effector  and  regulatory  links  of  the  adaptive  branch  are  usually
concomitant with this particular form of PICIS development (Manges et al.,  2004; Chere‐
pakhina et al., 2010c).
7. Clinical and immunological criteria of PICIS and state-of-the-art
algorithms of immunogenetic diagnostics of CDIO
The recommended diagnostic ideology relies on the combination of two categories of
screening procedures, viz.:
1. pathogenesis-oriented diagnosis of PICIS forms;
2. etiotropic diagnosis of microbial factors as the major PICIS provoker during chroniza‐
tion and progression of the infectious disease.
We have elaborated several criteria for substantiated clinical diagnosis of PICIS.
The following criteria should be taken into consideration during screening of abnormalities
(immune complex test)
1. innate branch: selective phagocytosis and natural cytotoxicity (NCT) indexes, base func‐
tions of dendritic (DC) and Ag-presenting (APC) cells, in some cases, complement com‐
ponents;
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2. adaptive branch: selective typing of effector and (in cases only) regulatory links of immun‐
ity combined with blood serotyping on antitarget auto-Abs and identification of Abs
against mimicking Ag determinants (Khaitov & Pinegin, 2000; Bach, 2005).
The criteria for etiotropic diagnostics (construction/design of the microbial landscape map)
taking account of newest advances in developing molecular and biological technologies, in‐
cluding achievements of metabolomics and metagenomics include the following:
1. spectrum and localization of microbial gene pools;
2. serological profile of antimicrobial Abs.
It may be inferred from the aforementioned that the therapeutic management of such pa‐
tients should include not only eradication of the infectious agent, but also immunocorrection
(in fact, the elimination of PICIS), which is especially important in patients with relapses
and frequent alternation of exacerbation and remission periods.
8. Conclusion
Many currently known infectious pathologies are characterized by persistent growth of the
CDIO link associated with conditionally pathogenic microorganisms, viruses, intracellular
parasites and other endogenous pathogenic microorganisms, particularly those manifesting
atypical properties (such as multiple resistance to antimicrobial drugs). At the same time,
patients with such pathologies manifest not only low-level immune reactivity, but also inad‐
equate immune responsiveness to the infectious process.
Numerous studies have shown that concrete forms of PICIS have clinical and prognostic sig‐
nificance for CDIO, because it is PICIS that determines, in a large measure, the progression
and chronization of the underlying disease and predicts the risk of complications.
PIFSI is a monosyndromal and dominant form of PICIS in patients with chronic infectious
pathologies.
At the same time, a different form of PICIS characteristic of immune autoaggression of PI‐
FASID or an associated form of immunopathology was recorded in more than 30% of cases.
Under these conditions, the form of PICIS and, correspondingly, the degree of immune dis‐
orders in patients with CDIO correlate, in an associative manner, with the severity of the
clinical course of the disease and the specific peculiarities of microbiocoenosis and their inter‐
action with the immune system of the patient. Therefore, any neglect of the results of the
interaction between the microbial factor and the host organism implies the risk of appear‐
ance of novel specific resistant forms of microorganisms that weaken the immune respon‐
siveness of the host organism and complicate the clinical course of the disease by promoting
its chronization and by worsening prognosis. A certain contribution to aggravation and pro‐
gression of the pathology is made by uncontrolled intake of antibiotics with a vast array of
immunosuppressive properties and other pharmacological activities.
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Recent progress in the study of the pathogenesis of autoimmune diseases may open up fresh
opportunities for the recovery of lost or defective immune system functions, development
and implementation of autoimmune diseases in the clinic qualitatively new treatment-and-
rehabilitation technologies based on the use of the most advanced applied molecular biolo‐
gy and immunology strategies.
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